Page last updated: 2024-12-08

arginylarginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Arg-Arg : A dipeptide formed from two L-arginine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID151956
CHEMBL ID296756
CHEBI ID73811
SCHEMBL ID288599
MeSH IDM0206159

Synonyms (26)

Synonym
arginyl-arginine
arginylarginine
bdbm50188488
2-((s)-2-amino-5-guanidino-1-oxo-pentylamino)-5-guanidino-pentanoic acid
arg-arg
chebi:73811 ,
CHEMBL296756 ,
(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
15483-27-9
l-arginine, n2-l-arginyl-
arginyl-l-arginine
h-arg-arg-oh acetate salt
l-arginyl-l-arginine
rr
l-arg-l-arg
SCHEMBL288599
arginyl-arginin
DTXSID60165745
r-r dipeptide
arginine arginine dipeptide
rr dipeptide
arginine-arginine dipeptide
Q27144127
(s)-2-((s)-2-amino-5-guanidinopentanamido)-5-guanidinopentanoic acid
CS-0447206
(s)-2-((s)-2-amino-5-guanidinopentanamido)-5-guanidinopentanoicacid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, the limited solubility and poor bioavailability of triterpene sapogenins restrict their therapeutic application."( Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
Li, X; Liu, K; Na, H; Wang, C; Zou, C, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)7,310.00000.18000.19000.2000AID266249
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)7,310.00000.00020.660310.0000AID266249
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1305424Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID1305430Therapeutic index, ratio of HC50 for human erythrocytes to MIC for Bacillus subtilis ATCC 66332016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
AID1305429Therapeutic index, ratio of HC50 for human erythrocytes to MIC for Staphylococcus aureus ATCC 259232016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
AID1305428Toxicity against human erythrocytes assessed as hemolysis after 1 hr by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
AID1305427Antibacterial activity against Escherichia coli ATCC 25922 after 16 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
AID1305426Antibacterial activity against Bacillus subtilis ATCC 6633 after 16 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Triterpene sapogenin-polyarginine conjugates exhibit promising antibacterial activity against Gram-positive strains.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (10.53)18.7374
1990's2 (10.53)18.2507
2000's5 (26.32)29.6817
2010's10 (52.63)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]